- Parataxis acquires Bridge Biotherapeutics to build Bitcoin treasury in Korea.
- South Korea named key market in Parataxis’ institutional Bitcoin strategy.
- Leadership changes follow acquisition; Andrew Kim appointed Parataxis Korea CEO.
Parataxis Holdings has announced a major move into the Asian market with the acquisition of Bridge Biotherapeutics, a biotech company listed on South Korea’s KOSDAQ exchange. Its value is estimated at 25 billion Korean won or approximately 18.5 million U.S. dollars. Once the transaction is done, the company will be renamed as Parataxis Korea, and it would still be listed in the KOSDAQ.
Parataxis Eyes South Korea as Next Hub for Institutional Bitcoin Access
The acquisition marks a major milestone for Parataxis Holdings. It plans to build South Korea’s first institutionally supported Bitcoin treasury platform. For example, similar models in the United States and Japan such as Strategy and Metaplanet have inspired this move. As a result, Parataxis aims to offer easier access to Bitcoin through public markets. This step also strengthens its position in Asia’s growing digital asset space. South Korea is also regarded as one of the main markets by the firm in terms of its future adoption of digital assets.
There are some conditions to which the deal remains pending such as the consent of the shareholders of Bridge Biotherapeutics. Upon its completion, the new entity will be a Bitcoin-native treasury-investment company whose core will be comprised of an expansive experience in the digital asset sector.
The transaction will be followed with leadership changes. Innovation Edward Chin, CEO and Founder of Parataxis Holdings, will become the new Board of Directors. Andrew Kim, a Parataxis Capital partner, will become a new Parataxis Korea CEO and a board member. In the meantime, James Jungkue Lee another co-founder of Bridge Biotherapeutics will still be at the forefront of the core operations of biotech and will still be on board.
Andrew Kim noted that they believed in long-term value of the project. South Korea is emerging as an important member in the adoption of Bitcoins. Its platform also helps us to provide institutions with a secure and well-regulated route towards being exposed to BTC, he added. He also signified the significance of the good financial practice and openness.
Parataxis Expands Bitcoin Strategy for Institutional Investors in Asia
Edward Chin also shared his thoughts on the deal. Edward Chin said the deal would benefit both shareholders and the nation. He emphasized that holding Bitcoin in South Korea is a smart move. Moreover, he noted that Bitcoin’s limited supply increases its long-term value. As a result, he called it a powerful and strategic asset.
In this strategy, Parataxis Holdings is also introducing a new investment fund that is similar in nature. More fund vehicles will also be coming up. Such attempts are designed to increase the amount of access to a digital asset and facilitate the wider strategy of Bitcoin treasury.
The company will update further following a shareholders meeting which is likely to take place in August. Shin & Kim LLC are offering legal support to the deal and Deloitte provided the financial support.
Parataxis Capital Management began in 2019 and concentrates on a diversified variety of digital asset investments. It gives management to many high-net-worth hedge funds and wealth advisory services for its institutions. The firm has an affiliate that is currently on the forefront to introducing Bitcoin-oriented investment strategies into legitimate areas in the financial markets first in South Korea.
By making such a bold move, Parataxis is not only investing in Bitcoin but also shaping the future of institutional crypto adoption in Asia. Moreover, this step signals growing confidence in integrating digital assets into traditional financial systems across the region.
The post Parataxis Acquires Korean Biotech Firm to Launch Bitcoin Treasury Platform appeared first on Live Bitcoin News.
